Table 2 Randomized phase III trials investigating first-line chemotherapy regimens in metastatic bladder TCC
From: Chemotherapy in advanced bladder cancer: current status and future
Authors | Journal or meeting | Year | Treatments | No | Results | Toxicity |
|---|---|---|---|---|---|---|
Logothetis [13] | JCO | 1990 | MVAC vs. CISCA | 120 | Sup: ORR = 65 vs. 46%, p < 0.05, and OS = 62.6 vs. 48.3 weeks | Sup |
Loehrer [14] | JCO | 1992 | MVAC vs. Cisplatin | 146 | Sup: ORR = 39 vs. 12%, p < 0.0001; PFS = 10 vs. 4.3 months, and OS = 12.5 vs. 8.2 months | Sup |
JCO | 2000 | MVAC vs. GC | 405 | Equivalents | more neutropenic sepsis (12% vs. 1%; P < 0.001) and more grade 3-4 mucositis (22% vs. 1%; P = 0.001) on the MVAC arm | |
JCO | 2001 | HD-MVAC vs. MVAC | 259 | Equivalents | less neutropenic fever (10% vs. 26%; P < 0.001) and mucositis on the HD-MVAC arm | |
Bamias [26] | JCO | 2004 | MVAC vs. DC | 120 | Sup | Â |
Dreicer [31] | Cancer | 2004 | MVAC vs. PCa | 85 | Interrupted early | Sup |
Bellmunt [48] | ASCO | 2007 | PCG vs. GC | 627 | Equivalents | Sup |
De Santis [37] | ASCO | 2010 | GCa vs. MCAVI | 238 | Equivalents | Inf |
Bamias [20] | ASCO | 2011 | DD-GC vs. HD-MVAC | 175 | Equivalents | Inf |